Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912133272> ?p ?o ?g. }
- W2912133272 endingPage "307" @default.
- W2912133272 startingPage "290" @default.
- W2912133272 abstract "The penicillin family of antibiotics remains an important part of our antimicrobial armamentarium. In general, these agents have bactericidal activity, excellent distribution throughout the body, low toxicity, and efficacy against infections caused by susceptible bacteria. The initial introduction of aqueous penicillin G for treatment of streptococcal and staphylococcal infections was an important pharmacologic landmark. The emergence of penicillinase-producing Staphylococcus aureus prompted the development of the penicillinase-resistant penicillins (for example, methicillin, oxacillin, and nafcillin), in which an acyl side chain prevented disruption of the β-lactamase ring. Subsequently, the aminopenicillins (ampicillin, amoxicillin, and bacampicillin) were developed because of the need for gram-negative antimicrobial activity. Their spectrum initially included Escherichia coli, Proteus mirabilis, Shigella, Salmonella, Listeria, Haemophilus, and Neisseria. The search for a penicillin with additional antimicrobial activity against the Enterobacteriaceae and Pseudomonas aeruginosa led to the development of the carboxypenicillins (carbenicillin and ticarcillin) and the ureidopenicillins (mezlocillin, azlocillin, and piperacillin). Finally, the combination of a β-lactamase inhibitor (clavulanic acid, sulbactam, or tazobactam) and an aminopenicillin, ticarcillin, or piperacillin has further extended their anti-bacterial spectra by inhibiting certain β-lactamases (nongroup 1) of resistant bacteria. The development of an ideal penicillin that is rapidly bactericidal, nonsensitizing, non-toxic, bioavailable, and resistant to β-lactamases and that has a high affinity for penicillin-binding proteins remains the goal. The penicillin family of antibiotics remains an important part of our antimicrobial armamentarium. In general, these agents have bactericidal activity, excellent distribution throughout the body, low toxicity, and efficacy against infections caused by susceptible bacteria. The initial introduction of aqueous penicillin G for treatment of streptococcal and staphylococcal infections was an important pharmacologic landmark. The emergence of penicillinase-producing Staphylococcus aureus prompted the development of the penicillinase-resistant penicillins (for example, methicillin, oxacillin, and nafcillin), in which an acyl side chain prevented disruption of the β-lactamase ring. Subsequently, the aminopenicillins (ampicillin, amoxicillin, and bacampicillin) were developed because of the need for gram-negative antimicrobial activity. Their spectrum initially included Escherichia coli, Proteus mirabilis, Shigella, Salmonella, Listeria, Haemophilus, and Neisseria. The search for a penicillin with additional antimicrobial activity against the Enterobacteriaceae and Pseudomonas aeruginosa led to the development of the carboxypenicillins (carbenicillin and ticarcillin) and the ureidopenicillins (mezlocillin, azlocillin, and piperacillin). Finally, the combination of a β-lactamase inhibitor (clavulanic acid, sulbactam, or tazobactam) and an aminopenicillin, ticarcillin, or piperacillin has further extended their anti-bacterial spectra by inhibiting certain β-lactamases (nongroup 1) of resistant bacteria. The development of an ideal penicillin that is rapidly bactericidal, nonsensitizing, non-toxic, bioavailable, and resistant to β-lactamases and that has a high affinity for penicillin-binding proteins remains the goal. CorrectionMayo Clinic ProceedingsVol. 74Issue 11PreviewIn the article by Wright entitled “The Penicillins,” published in the March 1999 issue of Mayo Clinic Proceedings (Mayo Clin Proc. 1999;74:290-307), Tables 2 and 4 contained several omissions and errors. In Table 2, for amoxicillin, the cost per daily dose should be $1.20—500 mg t.i.d. and $2.05—875 mg b.i.d.; and for amoxicillin-clavulanic acid, the cost per daily dose should be $10.69— 500 mg t.i.d. and $9.52—875 mg b.i.d In Table 4, oral administration of amoxicillin-clavulanic acid should also include 875 b.i.d. Full-Text PDF" @default.
- W2912133272 created "2019-02-21" @default.
- W2912133272 creator A5038868077 @default.
- W2912133272 date "1999-03-01" @default.
- W2912133272 modified "2023-09-25" @default.
- W2912133272 title "The Penicillins" @default.
- W2912133272 cites W1492940396 @default.
- W2912133272 cites W1499482268 @default.
- W2912133272 cites W1519049852 @default.
- W2912133272 cites W1569573424 @default.
- W2912133272 cites W1972985689 @default.
- W2912133272 cites W1984864482 @default.
- W2912133272 cites W1992375269 @default.
- W2912133272 cites W1993694579 @default.
- W2912133272 cites W1999698054 @default.
- W2912133272 cites W2013627667 @default.
- W2912133272 cites W2014183316 @default.
- W2912133272 cites W2015873572 @default.
- W2912133272 cites W2018478163 @default.
- W2912133272 cites W2028218479 @default.
- W2912133272 cites W2030655700 @default.
- W2912133272 cites W2034990069 @default.
- W2912133272 cites W2038191587 @default.
- W2912133272 cites W2040045396 @default.
- W2912133272 cites W2057468404 @default.
- W2912133272 cites W2061224849 @default.
- W2912133272 cites W2062331166 @default.
- W2912133272 cites W2062856928 @default.
- W2912133272 cites W2079858511 @default.
- W2912133272 cites W2079989516 @default.
- W2912133272 cites W2086148176 @default.
- W2912133272 cites W2086773685 @default.
- W2912133272 cites W2091416345 @default.
- W2912133272 cites W2091950027 @default.
- W2912133272 cites W2092737677 @default.
- W2912133272 cites W2104603291 @default.
- W2912133272 cites W2105812191 @default.
- W2912133272 cites W2116649852 @default.
- W2912133272 cites W2121282317 @default.
- W2912133272 cites W2152068353 @default.
- W2912133272 cites W2164216634 @default.
- W2912133272 cites W2310331532 @default.
- W2912133272 cites W2318331638 @default.
- W2912133272 cites W2320987882 @default.
- W2912133272 cites W2325858025 @default.
- W2912133272 cites W2331269357 @default.
- W2912133272 cites W2336214247 @default.
- W2912133272 cites W2338918714 @default.
- W2912133272 cites W2603578809 @default.
- W2912133272 cites W4249916069 @default.
- W2912133272 cites W4302076018 @default.
- W2912133272 cites W4302324801 @default.
- W2912133272 doi "https://doi.org/10.4065/74.3.290" @default.
- W2912133272 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10090000" @default.
- W2912133272 hasPublicationYear "1999" @default.
- W2912133272 type Work @default.
- W2912133272 sameAs 2912133272 @default.
- W2912133272 citedByCount "144" @default.
- W2912133272 countsByYear W29121332722012 @default.
- W2912133272 countsByYear W29121332722013 @default.
- W2912133272 countsByYear W29121332722014 @default.
- W2912133272 countsByYear W29121332722015 @default.
- W2912133272 countsByYear W29121332722016 @default.
- W2912133272 countsByYear W29121332722017 @default.
- W2912133272 countsByYear W29121332722018 @default.
- W2912133272 countsByYear W29121332722019 @default.
- W2912133272 countsByYear W29121332722020 @default.
- W2912133272 countsByYear W29121332722021 @default.
- W2912133272 countsByYear W29121332722022 @default.
- W2912133272 countsByYear W29121332722023 @default.
- W2912133272 crossrefType "journal-article" @default.
- W2912133272 hasAuthorship W2912133272A5038868077 @default.
- W2912133272 hasConcept C174802600 @default.
- W2912133272 hasConcept C2776083883 @default.
- W2912133272 hasConcept C2776536040 @default.
- W2912133272 hasConcept C2777637488 @default.
- W2912133272 hasConcept C2778193466 @default.
- W2912133272 hasConcept C2779454058 @default.
- W2912133272 hasConcept C2779708577 @default.
- W2912133272 hasConcept C4937899 @default.
- W2912133272 hasConcept C501593827 @default.
- W2912133272 hasConcept C523546767 @default.
- W2912133272 hasConcept C54355233 @default.
- W2912133272 hasConcept C71924100 @default.
- W2912133272 hasConcept C86803240 @default.
- W2912133272 hasConcept C89423630 @default.
- W2912133272 hasConceptScore W2912133272C174802600 @default.
- W2912133272 hasConceptScore W2912133272C2776083883 @default.
- W2912133272 hasConceptScore W2912133272C2776536040 @default.
- W2912133272 hasConceptScore W2912133272C2777637488 @default.
- W2912133272 hasConceptScore W2912133272C2778193466 @default.
- W2912133272 hasConceptScore W2912133272C2779454058 @default.
- W2912133272 hasConceptScore W2912133272C2779708577 @default.
- W2912133272 hasConceptScore W2912133272C4937899 @default.
- W2912133272 hasConceptScore W2912133272C501593827 @default.
- W2912133272 hasConceptScore W2912133272C523546767 @default.
- W2912133272 hasConceptScore W2912133272C54355233 @default.
- W2912133272 hasConceptScore W2912133272C71924100 @default.